StemRIM (4599.T)
JPY 298.0
(0.0%)
JPY 298.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 2.07 Billion JPY | -5.96% |
| 2023 | 2.2 Billion JPY | 10.18% |
| 2022 | 2 Billion JPY | 0.5% |
| 2021 | 1.99 Billion JPY | 18.37% |
| 2020 | 1.68 Billion JPY | 103.7% |
| 2019 | 826.86 Million JPY | 43.77% |
| 2018 | 575.14 Million JPY | 24.82% |
| 2017 | 460.76 Million JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 507.33 Million JPY | -4.47% |
| 2024 Q4 | 524 Million JPY | 3.27% |
| 2024 Q2 | 531.08 Million JPY | 8.05% |
| 2024 Q1 | 491.51 Million JPY | -19.81% |
| 2023 Q2 | 529.34 Million JPY | 3.23% |
| 2023 FY | 2.2 Billion JPY | 10.18% |
| 2023 Q1 | 512.75 Million JPY | 8.09% |
| 2023 Q4 | 612.95 Million JPY | 10.93% |
| 2023 Q3 | 552.55 Million JPY | 4.39% |
| 2022 Q2 | 516.71 Million JPY | 0.76% |
| 2022 FY | 2 Billion JPY | 0.5% |
| 2022 Q4 | 474.36 Million JPY | -5.08% |
| 2022 Q3 | 499.74 Million JPY | -3.28% |
| 2022 Q1 | 512.83 Million JPY | 4.76% |
| 2021 FY | 1.99 Billion JPY | 18.37% |
| 2021 Q4 | 489.51 Million JPY | -5.31% |
| 2021 Q3 | 516.97 Million JPY | 1.61% |
| 2021 Q2 | 508.8 Million JPY | 6.35% |
| 2021 Q1 | 478.43 Million JPY | -46.41% |
| 2020 FY | 1.68 Billion JPY | 103.7% |
| 2020 Q4 | 892.69 Million JPY | 173.53% |
| 2020 Q3 | 326.36 Million JPY | 31.44% |
| 2020 Q2 | 248.3 Million JPY | 14.47% |
| 2020 Q1 | 216.92 Million JPY | -1.66% |
| 2019 FY | 826.86 Million JPY | 43.77% |
| 2019 Q4 | 220.59 Million JPY | 0.0% |
| 2018 FY | 575.14 Million JPY | 24.82% |
| 2017 FY | 460.76 Million JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.28 Billion JPY | -61.623% |
| PRISM BioLab Co.,LTD | 576.81 Million JPY | -259.907% |
| GNI Group Ltd. | 9.32 Billion JPY | 77.731% |
| Linical Co., Ltd. | 2.7 Billion JPY | 23.259% |
| Trans Genic Inc. | 2.15 Billion JPY | 3.881% |
| MEDINET Co., Ltd. | 1.49 Billion JPY | -39.221% |
| Soiken Holdings Inc. | 3.07 Billion JPY | 32.401% |
| Cytori Cell Research Institute, Inc. | 1.85 Billion JPY | -11.795% |
| AnGes, Inc. | 8.9 Billion JPY | 76.68% |
| OncoTherapy Science, Inc. | 943.08 Million JPY | -120.13% |
| Nxera Pharma Co., Ltd. | 19.19 Billion JPY | 89.182% |
| Immuno-Biological Laboratories Co., Ltd. | 412.99 Million JPY | -402.676% |
| NanoCarrier Co., Ltd. | 975.37 Million JPY | -112.842% |
| Carna Biosciences, Inc. | 2.56 Billion JPY | 19.145% |
| CanBas Co., Ltd. | 278 Million JPY | -646.763% |
| D. Western Therapeutics Institute, Inc. | 1.14 Billion JPY | -81.86% |
| RaQualia Pharma Inc. | 1.81 Billion JPY | -14.195% |
| Chiome Bioscience Inc. | 1.6 Billion JPY | -29.446% |
| Kidswell Bio Corporation | 2.37 Billion JPY | 12.555% |
| PeptiDream Inc. | 9.68 Billion JPY | 78.57% |
| Oncolys BioPharma Inc. | 1.96 Billion JPY | -5.886% |
| Ribomic Inc. | 1.1 Billion JPY | -87.756% |
| SanBio Company Limited | 4.53 Billion JPY | 54.263% |
| Healios K.K. | 3.48 Billion JPY | 40.465% |
| BrightPath Biotherapeutics Co., Ltd. | 1.15 Billion JPY | -79.781% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 1.33 Billion JPY | -55.568% |
| Delta-Fly Pharma, Inc. | 1.4 Billion JPY | -47.92% |
| CellSource Co., Ltd. | 1.96 Billion JPY | -5.73% |
| FunPep Company Limited | 313.82 Million JPY | -561.524% |
| Kringle Pharma, Inc. | 958.01 Million JPY | -116.699% |
| Stella Pharma Corporation | 963.98 Million JPY | -115.356% |
| TMS Co., Ltd. | 943.25 Million JPY | -120.089% |
| Noile-Immune Biotech Inc. | 1.08 Billion JPY | -90.467% |
| Cuorips Inc. | 598.11 Million JPY | -247.089% |
| K Pharma,Inc. | 543.94 Million JPY | -281.658% |
| Takara Bio Inc. | 23.9 Billion JPY | 91.316% |
| ReproCELL Incorporated | 1.51 Billion JPY | -37.119% |
| PhoenixBio Co., Ltd. | 1.18 Billion JPY | -75.339% |
| StemCell Institute Inc. | 1.16 Billion JPY | -78.639% |
| Japan Tissue Engineering Co., Ltd. | 1.52 Billion JPY | -36.375% |
| CellSeed Inc. | 804.93 Million JPY | -157.91% |